CLINICAL TRIALS PROFILE FOR MEPRON

All Clinical Trials for MEPRON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00405860 ↗	CellCept in p-ANCA Vasculitis	Completed	Roche Pharma AG	Phase 1	2002-12-01	Microscopic polyangiitis (MP) is a primary systemic vasculitis predominantly affecting small blood vessels. Following the widespread introduction of ANCA testing, the primary systemic vasculitis (SV), Wegener?s granulomatosis (WG) and microscopic polyangiitis (MP) appear to be more frequent than was previously thought (see definitions in Appendix 6). In addition, the existence of early and organ-limited forms of these diseases, such as renal-limited vasculitis (RLV) is now clearly recognized. Their annual incidence exceeds 20 per million per year and they account for at least 5 % of the causes of end stage renal failure. The two diseases share many features of their histology, serology and response to treatment, pointing to similarities in their pathogenesis, which have justified a common approach to their management. The standard treatment with corticosteroids (CS) and cyclophosphamide (CYC) is usually effective at controlling active disease but continued treatment is necessary to prevent disease relapse. Due to the cumulative toxicity associated with CYC treatment, alternatives have been looked for. Mycophenolate mofetil (MMF) has been used to treat patients with a variety of immune-mediated nephritides, including ANCA-associated vasculitis, with less toxicity than CYC but with variable outcome. The present trial will examine whether substitution of oral CYC with oral MMF is equally efficient for induction of remission with less adverse effects in cases of MP with mild to moderate renal involvement. All patients will receive the same regimen of oral prednisone + MMF. Prednisone will be tapered to a stop after 24 weeks but MMF will continue for a total of 18 months unless there is worsening or persistent disease. The trial ends after 18 months.
NCT00405860 ↗	CellCept in p-ANCA Vasculitis	Completed	Mayo Clinic	Phase 1	2002-12-01	Microscopic polyangiitis (MP) is a primary systemic vasculitis predominantly affecting small blood vessels. Following the widespread introduction of ANCA testing, the primary systemic vasculitis (SV), Wegener?s granulomatosis (WG) and microscopic polyangiitis (MP) appear to be more frequent than was previously thought (see definitions in Appendix 6). In addition, the existence of early and organ-limited forms of these diseases, such as renal-limited vasculitis (RLV) is now clearly recognized. Their annual incidence exceeds 20 per million per year and they account for at least 5 % of the causes of end stage renal failure. The two diseases share many features of their histology, serology and response to treatment, pointing to similarities in their pathogenesis, which have justified a common approach to their management. The standard treatment with corticosteroids (CS) and cyclophosphamide (CYC) is usually effective at controlling active disease but continued treatment is necessary to prevent disease relapse. Due to the cumulative toxicity associated with CYC treatment, alternatives have been looked for. Mycophenolate mofetil (MMF) has been used to treat patients with a variety of immune-mediated nephritides, including ANCA-associated vasculitis, with less toxicity than CYC but with variable outcome. The present trial will examine whether substitution of oral CYC with oral MMF is equally efficient for induction of remission with less adverse effects in cases of MP with mild to moderate renal involvement. All patients will receive the same regimen of oral prednisone + MMF. Prednisone will be tapered to a stop after 24 weeks but MMF will continue for a total of 18 months unless there is worsening or persistent disease. The trial ends after 18 months.
NCT03568994 ↗	Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)	Active, not recruiting	Texas Children's Hospital	Early Phase 1	2018-07-10	This study will test daily dosing of atovaquone at established pneumocystis jiroveci pneumonia (PJP) prophylaxis dosing in combination with standard induction chemotherapy for de novo AML. The primary objectives are to determine the frequency of omission of atovaquone doses due to standard induction chemotherapy toxicity, to quantify the steady-state plasma levels of atovaquone, and to determine the time to achievement of steady state atovaquone levels in this population.

Clinical Trial Conditions for MEPRON

Condition Name

Condition Name for MEPRON
Intervention	Trials
Acute Myeloid Leukemia	1
Microscopic Polyangiitis	1
MPO-ANCA Vasculitis	1

Condition MeSH

Condition MeSH for MEPRON
Intervention	Trials
Leukemia, Myeloid, Acute	1
Leukemia, Myeloid	1
Leukemia	1

Clinical Trial Locations for MEPRON

Trials by Country

Trials by Country for MEPRON
Location	Trials
United States	3

Trials by US State

Trials by US State for MEPRON
Location	Trials
Texas	1
Maryland	1
Minnesota	1

Clinical Trial Progress for MEPRON

Clinical Trial Phase

Clinical Trial Phase for MEPRON
Clinical Trial Phase	Trials
Phase 1	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for MEPRON
Clinical Trial Phase	Trials
Active, not recruiting	1
Completed	1

Clinical Trial Sponsors for MEPRON

Sponsor Name

Sponsor Name for MEPRON
Sponsor	Trials
Mayo Clinic	1
Texas Children's Hospital	1
William Marsh Rice University	1

Sponsor Type

Sponsor Type for MEPRON
Sponsor	Trials
Other	4
Industry	1

MEPRON Market Analysis and Financial Projection

Last updated: May 3, 2026

MEPRON (mepron): Clinical Trials Update and Market Analysis With Forecast

MEPRON is atovaquone oral suspension (brand “Mepron”); its main commercial use is treatment of Pneumocystis jirovecii pneumonia (PJP) in patients who cannot use or tolerate first-line regimens. The latest clinical-trial landscape for atovaquone is dominated by older registrations and limited new interventional activity, while demand is driven by guideline-based PJP prophylaxis and treatment patterns, hospital formularies, and access dynamics for generic atovaquone products.

---

What is MEPRON and what is the current clinical-trial posture for atovaquone?

Regulatory and clinical context

• Active ingredient: atovaquone
• Product form (brand reference): oral suspension (historically sold as “Mepron” and related formulations in multiple markets)
• Primary indication base: PJP treatment (and, in practice, prophylaxis use in certain populations), guided by standard of care in HIV-related and non-HIV immunocompromised settings.

Clinical trials update (interventional pipeline)

Interventional clinical activity for atovaquone is limited versus newer anti-infective and oncology pipelines. Published studies and ongoing registries typically emphasize:

• Comparative or adjunct studies in PJP and other opportunistic infections
• Pharmacokinetic evaluations (including suspension vs. formulation comparisons)
• Studies in special populations (pediatrics, HIV, immunosuppressed non-HIV cohorts)

In practical commercial terms, this translates to minimal “trial-driven” incremental label expansion for MEPRON at a brand level, with sales continuing to rely on standard-of-care utilization and generic competition rather than new indication wins.

Market implication: MEPRON’s near-term revenue trajectory is less sensitive to incremental trial readouts and more sensitive to (i) access to generic atovaquone, (ii) payer formularies, and (iii) inventory and supply stability.

---

What does the atovaquone market look like and how does MEPRON fit?

Demand drivers

• PJP incidence in at-risk populations: ART-era HIV epidemiology plus prophylaxis compliance drive the size of the treat-and-prevent population.
• Alternative regimen constraints: Atovaquone remains a key option when patients cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX) or when TMP-SMX is contraindicated.
• Non-HIV immunosuppression: Transplant, hematologic malignancy, and steroid-immunosuppressed populations contribute to steady prophylaxis and treatment demand.

Supply and competition structure

• Generic atovaquone penetration is central. MEPRON faces pricing pressure from generics and channel substitution.
• Brand differentiation is typically limited to availability, formulation consistency, and distribution contracts, not new clinical differentiation.
• Any brand premium depends on:
  • tender and hospital supply agreements
  • payer preferred status
  • contracted reimbursement and discounts

Pricing reality

Atovaquone’s market pricing tends to track generic competitive dynamics; brand leverage is usually strongest when generics face supply constraints or when payers restrict substitutions.

---

What is the market forecast and how will MEPRON perform?

Forecast framework

Because MEPRON lacks a clear near-term label expansion engine, the forecast should be treated as:

• Volume-led by treat-and-prophylaxis utilization, and
• Value-led by pricing versus generic erosion and access policies.

Base case projection (directional)

Base case: flat-to-declining net sales in mature markets due to generic substitution, with potential stabilization only where supply and payer contracting maintain brand share.

Upside case: brand share resilience driven by:

• restricted formulary decisions favoring brand supply,
• temporary generic shortages, and/or
• pediatric and institutional contract continuity.

Downside case: accelerating brand share loss if:

• more payers move to preferred generic-only,
• additional generic entrants reduce pricing,
• persistent supply issues shift volume to alternatives.

Key market indicators to monitor (deal-level)

• formulary status changes (preferred vs non-preferred)
• wholesaler fill rates and backorder frequency
• average realized price movements vs AWP benchmarks
• generic acquisition and tender pricing by hospital groups

---

Clinical and payer guidance: what determines utilization of atovaquone/MEPRON?

Guideline-aligned prescribing

Utilization follows prophylaxis and treatment algorithms for PJP:

• TMP-SMX is often first-line where tolerated.
• Atovaquone is used when TMP-SMX is not tolerated or contraindicated.
• In HIV and in non-HIV immunocompromised states, prophylaxis duration is tied to immunologic status or immunosuppression intensity.

Commercial implication: utilization is less about MEPRON-specific clinical breakthroughs and more about substitution behavior when TMP-SMX is avoided.

---

Competitive landscape: what substitutes compete with MEPRON?

Therapeutic alternatives

Atovaquone competes in the PJP setting with:

• TMP-SMX (first-line when tolerated)
• Dapsone (when suitable)
• Aerosolized pentamidine (selected prophylaxis use)
• Other regimen variants depending on local practice

Commercial implication: MEPRON’s competitive posture depends on tolerability profiles and local payer preferences, with generic atovaquone reducing differentiation risk.

---

What is the investment R&D signal for atovaquone now?

Innovation headwinds

• PJP treatment and prophylaxis pathways are mature.
• Resistance or novel target biology is not a major lever versus newer therapeutic areas.
• Trials tend to be incremental rather than label-expanding.

Where meaningful development can still occur

• formulation improvements that reduce variability in absorption,
• studies supporting use in under-served populations,
• health-economic evidence to secure formulary inclusion.

Net: MEPRON’s growth case is more likely to come from access economics than from new clinical-to-commercial conversion.

---

Key Takeaways

• MEPRON (atovaquone) has a mature clinical role in PJP treatment and prophylaxis patterns, with limited visible trial-driven label expansion.
• Market performance is primarily driven by generic atovaquone substitution, payer formularies, and access constraints, not by new indications.
• Near-term projection skews flat-to-declining in value in mature markets, with potential stabilization only if brand share holds via contracting or generic supply dynamics.
• Clinical trial updates have limited direct commercial impact unless they produce evidence for meaningful new use cases or formulary reclassifications.

---

FAQs

1) Is MEPRON expected to gain new indications from current atovaquone trials?
No clear indication of a near-term label expansion engine at brand level; pipeline activity is typically incremental.

2) What most affects MEPRON sales in practice?
Generic atovaquone price pressure and whether payers and hospitals prefer brand vs substitution.

3) What patient populations drive demand most?
Immunocompromised patients requiring PJP prophylaxis or treatment, including TMP-SMX-intolerant cohorts.

4) What are the closest therapeutic substitutes to MEPRON?
TMP-SMX, dapsone, and aerosolized pentamidine, depending on tolerability and setting.

5) What operational signals should a sponsor track for MEPRON commercialization risk?
Wholesaler fill rates, backorders, average realized price vs AWP, and formulary tier movement.

---

References

[1] U.S. Food and Drug Administration. Mepron (atovaquone) prescribing information / product labeling resources. FDA accessdata and label database.
[2] NIH. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV (PJP prophylaxis and treatment sections). National Institutes of Health.
[3] NIH. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With HIV (PJP prophylaxis and treatment sections). National Institutes of Health.
[4] Centers for Disease Control and Prevention. Pneumocystis pneumonia and HIV opportunistic infection epidemiology resources. CDC.
[5] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD classification for atovaquone (where applicable) and usage context.